open access

Vol 12, No 3 (2008)
REVIEV
Published online: 2008-05-29
Get Citation

Endothelial dysfunction and ADMA in pathogenesis of arterial hypertension

Adrian Doroszko, Ryszard Andrzejak, Andrzej Szuba
Nadciśnienie tętnicze 2008;12(3):224-237.

open access

Vol 12, No 3 (2008)
REVIEV
Published online: 2008-05-29

Abstract

Cardiovascular diseases (CVD) are today one of the major healthcare problems of the world population. Endothelial dysfunction (ED) reflects prominent abnormalities observed in these disorders. Nitric oxide is one of the most potent endothelial vasodilators and has also anti-inflammatory and antithrombotic properties. NO-mediated endothelium - dependent vasodilatation plays a crucial role in regulation of vascular tone. Impaired activity of NO-dependent metabolic pathways in endothelium may increase the risk of CVD and may be an important pathophysiological link leading to development of arterial hypertension (HTA). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase, which may cause ED due to decreased NO-availability. ADMA may be not only a marker, but also an active mediator in pathogenesis of CVD. Its levels have been shown to be elevated in variety of disorders, e.g. in hypertension. This article gives a brief review of contemporary state of knowledge regarding ED, ADMA and HTA. Pathophysiology of ED and HTA and possible pharmacological interventions aiming the modulation of ADMA level are discussed.

Abstract

Cardiovascular diseases (CVD) are today one of the major healthcare problems of the world population. Endothelial dysfunction (ED) reflects prominent abnormalities observed in these disorders. Nitric oxide is one of the most potent endothelial vasodilators and has also anti-inflammatory and antithrombotic properties. NO-mediated endothelium - dependent vasodilatation plays a crucial role in regulation of vascular tone. Impaired activity of NO-dependent metabolic pathways in endothelium may increase the risk of CVD and may be an important pathophysiological link leading to development of arterial hypertension (HTA). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase, which may cause ED due to decreased NO-availability. ADMA may be not only a marker, but also an active mediator in pathogenesis of CVD. Its levels have been shown to be elevated in variety of disorders, e.g. in hypertension. This article gives a brief review of contemporary state of knowledge regarding ED, ADMA and HTA. Pathophysiology of ED and HTA and possible pharmacological interventions aiming the modulation of ADMA level are discussed.
Get Citation

Keywords

endothelial dysfunction; ADMA; arterial hypertension

About this article
Title

Endothelial dysfunction and ADMA in pathogenesis of arterial hypertension

Journal

Arterial Hypertension

Issue

Vol 12, No 3 (2008)

Pages

224-237

Published online

2008-05-29

Bibliographic record

Nadciśnienie tętnicze 2008;12(3):224-237.

Keywords

endothelial dysfunction
ADMA
arterial hypertension

Authors

Adrian Doroszko
Ryszard Andrzejak
Andrzej Szuba

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl